• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register

AEE-788

Product ID A1616
Cas No. 497839-62-0
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $61.50 In stock
5 mg $135.90 In stock
25 mg $522.30 In stock
Bulk Quote
Add to Wishlist

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

AEE-788 is an inhibitor of EGFR, HER2, VEGFR2, and FLT3 that exhibits anticancer chemotherapeutic activity. In animal models with ependymoma xenografts, AEE-788 increases survival rates. In acute myelogenous leukemia (AML) cells, AEE-788 inhibits cell proliferation and induces apoptosis. This compound displays mixed results in a clinical setting due to high toxicity.

Product Info

Cas No.

497839-62-0

Purity

≥98%

Formula

C27H32N6

Formula Wt.

440.60

Chemical Name

6-{4-[(4-Ethyl-1-piperazinyl)methyl]phenyl}-N-[(1R)-1-phenylethyl]-1H-pyrrolo[2,3-d]pyrimidin-4-amine

IUPAC Name

6-{4-[(4-Ethyl-1-piperazinyl)methyl]phenyl}-N-[(1R)-1-phenylethyl]-1H-pyrrolo[2,3-d]pyrimidin-4-amine

Synonym

AEE788, NVP-AEE788

Solubility

100mM in DMSO insoluble in ethanol and H2O

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

A1616 MSDS PDF

Info Sheet

A1616 Info Sheet PDF

References

Baselga J, Mita AC, Schöffski P, et al. Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. Clin Cancer Res. 2012 Nov 15;18(22):6364-72. PMID: 23014528.

Servidei T, Meco D, Trivieri N, et al. Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models. Int J Cancer. 2012 Sep 1;131(5):E791-803. PMID: 22120695.

Reardon DA, Conrad CA, Cloughesy T, et al. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol. 2012 Jun;69(6):1507-18. PMID: 22392572.

Barbarroja N, Torres LA, Rodriguez-Ariza A, et al. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia. Exp Hematol. 2010 Aug;38(8):641-52. PMID: 20380868.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2023 LKT Laboratories, All Rights Reserved - Products for research use only